Show/hide main menu

News

News Highlights

CRESTAR project selected by Russell Group to showcase EU research

Posted on 18/04/2016
schizophrenia-crestar-puff

A King’s research project has been selected for a new section of The Russell Group’s website, which aims to showcase how UK membership of the European Union enhances world-class research and teaching at Russell Group universities.

One of 23 studies profiled on The Russell Group’s website, the EU-funded CRESTAR project will help to identify the most appropriate treatments for sufferers of schizophrenia and improve their prognosis.

By using a vast pool of clinical data and DNA samples taken from across Europe the team of researchers are able to establish the likelihood of a patient’s response to anti-psychotic drugs including clozapine, which is reserved for drug-resistant patients.

The research team, led by Dr James MacCabe and Professor David Collier from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN), then used this resource to establish what characteristics were common between groups who were and were not resistant to anti-psychotic drugs. The study paves the way for the development of biomarkers, genomic tests and clinical decision-making tools that enable doctors to see if a particular patient should be started on clozapine sooner in their illness.

A follow-on project named Strata, funded by the Medical Research Council, has begun to combine Crestar insights with neuroimaging measures and will continue this wide collaboration to make measurable improvements to the lives of those with mental health problems.

Rss Feed Atom Feed

News Highlights:

News Highlights...RSS FeedAtom Feed

Mindfulness-Based Cognitive Therapy linked to reduced risk of depressive relapse

Mindfulness-Based Cognitive Therapy linked to reduced risk of depressive relapse

Description
The largest meta-analysis so far of Mindfulness-Based Cognitive Therapy (MBCT) for recurrent depression has found that MBCT is an effective treatment option that can help prevent the recurrence of major depression.
New report shows electronic cigarettes are beneficial to UK public health

New report shows electronic cigarettes are beneficial to UK public health

Description
Electronic cigarettes have the potential to contribute significantly to reducing death and disability caused by Britain's biggest killer, say experts in The BMJ today, including Professor Ann McNeill from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London.
Smartphones and wearable devices could revolutionise medical care for people with brain disorders

Smartphones and wearable devices could revolutionise medical care for people with brain disorders

Description
A major new research programme supported by the Innovative Medicines Initiative (IMI) launches today [26 April], which will develop new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology.

Share this story:

 

Follow Us

@kingscollegelon

Live Twitter feed...

@kingscollegelon
Join the conversation
Sitemap Site help Terms and conditions Privacy policy Accessibility Modern slavery statement Contact us

© 2017 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454